Filed in archive
Studies
, Treatment
by Gloria Gamat on June 25, 2007
Before such findings, there was no effective treatment for macular radiation retinopathy - an eye condition brought about by radiation therapy in eye cancer patients.
Published in the current issue of the journal Archives of Ophthalmology, Avastin® has been found to reduce abnormal blood vessel growth and stops leakage in the eye -- allowing patients who were destined to go blind within five years to retain their vision longer.
According to Dr. Paul T. Finger, lead author of the study and director of Ocular Tumor Services at the New York Eye and Ear Infirmary:
"This is a major breakthrough for eye cancer patients who are treated with radiation therapy and commonly develop radiation retinopathy."
A product of Genentech, Avastin® (bevacizumab) is the first US FDA-approved therapy designed to inhibit angiogenesis - the process by which new blood vessels develop and carry vital nutrients to a tumor.
Read the full report.
Permalink: Cancer Drug Avastin® May Help Save Vision
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/77455
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Cancer Drug Avastin® May Help Save Vision:
|
Rating: 5.00 out of 2 vote(s) cast.
|
Response from:
Frank
(03/10/09 8:40pm)
Treatment began March 11, 2009: contact me for progress
Response from:
Trusted.MD Network
Use of the cancer drug Avastin® may help keep the eyesight longer of patients with radiation retinopathy. Before such findings, there was no effective treatment for macular radiation retinopathy - an eye condition brought about by radiation therapy in ey
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
